Abstract
We previously reported that the PPARγ agonist troglitazone (TRO) inhibits proliferation and induces apoptosis in human MCF-7 breast carcinoma cells. To understand the mechanisms of antiproliferative and pro-apoptotic effects of TRO, we screened a limited DNA array containing 23 genes involved in regulating either the cell cycle and/or apoptosis. Four of the 23 genes screened exhibited regulation by TRO, with growth arrest and DNA damage-inducible gene 45 (GADD45) being the most strongly upregulated. TRO induced GADD45 mRNA expression in a time- and dose-dependent manner. Depletion of GADD45 by siRNA abrogated TRO-induced apoptosis in MCF-7 cells demonstrating the physiological relevance of GADD45 upregulation. Signaling pathways mediating TRO-induced GADD45 were also investigated. Several mitogen-activated protein kinase (MAPK) pathways were involved in the induction of GADD45 by TRO. Inhibition of the c-jun N-terminal kinase MAPK pathway by SP600125 partially abolished TRO-induced GADD45 mRNA, and protein expression and apoptosis. In contrast, inhibition of the p38 MAPK pathway by SB203580, or through overexpression of a dominant-negative mutant of p38 MAPK, augmented GADD45 mRNA induction and GADD45 promoter activation as well as cell apoptosis by TRO. Blockade of the extracellular signal-regulated kinase MAPK pathway by PD98059 also enhanced TRO's effects on GADD45 and apoptosis. Two other PPARγ agonists pioglitazone and rosiglitazone did not induce GADD45 expression. Our finding of GADD45 induction by TRO may provide a new insight concerning the mechanisms for TRO's antiproliferative and pro-apoptotic effects in breast cancer cells.
Similar content being viewed by others
References
Asou H, Verbeek W, Williamson E, Elstner E, Kubota T, Kamada N and Koeffler HP . (1999). Int. J. Oncol., 15, 1027–1031.
Bae MA and Song BJ . (2003). Mol. Pharmacol., 63, 401–408.
Begum NM, Nakashiro K, Kawamata H, Uchida D, Shintani S, Ikawa Y, Sato M and Hamakawa H . (2002). Int. J. Oncol., 20, 599–605.
Bruemmer D, Yin F, Liu J, Berger JP, Sakai T, Blaschke F, Fleck E, Van Herle AJ, Forman BM and Law RE . (2003). Circ. Res., 93, 38–47.
Carrier F, Georgel PT, Pourquier P, Blake M, Kontny HU, Antinore MJ, Gariboldi M, Myers TG, Weinstein JN, Pommier Y and Fornace Jr. AJ . (1999). Mol Cell Biol, 19, 1673–1685.
Chang TH and Szabo E . (2000). Cancer Res., 60, 1129–1138.
Chen C . (1998). Am. J. Health Syst. Pharm., 55, 905–925.
Chen F, Zhang Z, Leonard SS and Shi X . (2001). Oncogene, 20, 3585–3589.
Chen IT, Smith ML, O'Connor PM and Fornace Jr. AJ . (1995). Oncogene, 11, 1931–1937.
Chitturi S and George J . (2002). Semin. Liver Dis., 22, 169–183.
Clay CE, Namen AM, Atsumi G, Willingham MC, High KP, Kute TE, Trimboli AJ, Fonteh AN, Dawson PA and Chilton FH . (1999). Carcinogenesis, 20, 1905–1911.
Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman BM and Singer S . (1999). Proc. Natl. Acad. Sci. USA, 96, 3951–3956.
Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D and Koeffler HP . (1998). Proc. Natl. Acad. Sci. USA, 95, 8806–8811.
Finkel T and Holbrook NJ . (2000). Nature, 408, 239–247.
Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I and Horikoshi H . (1988). Diabetes, 37, 1549–1558.
Haydon RC, Zhou L, Feng T, Breyer B, Cheng H, Jiang W, Ishikawa A, Peabody T, Montag A, Simon MA and He TC . (2002). Clin. Cancer Res., 8, 1288–1294.
Hisatake JI, Ikezoe T, Carey M, Holden S, Tomoyasu S and Koeffler HP . (2000). Cancer Res., 60, 5494–5498.
Huin C, Schohn H, Hatier R, Bentejac M, Antunes L, Plenat F, Bugaut M and Dauca M . (2002). Biol. Cell, 94, 15–27.
Kearsey JM, Coates PJ, Prescott AR, Warbrick E and Hall PA . (1995). Oncogene, 11, 1675–1683.
Kostrubsky VE, Sinclair JF, Ramachandran V, Venkataramanan R, Wen YH, Kindt E, Galchev V, Rose K, Sinz M and Strom SC . (2000). Drug Metab. Dispos., 28, 1192–1197.
Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I and Koeffler HP . (1998). Cancer Res., 58, 3344–3352.
Kultz D, Madhany S and Burg MB . (1998). J. Biol. Chem., 273, 13645–13651.
Lowell BB . (1999). Cell, 99, 239–242.
Mita H, Tsutsui J, Takekawa M, Witten EA and Saito H . (2002). Mol. Cell Biol., 22, 4544–4555.
Mossner R, Schulz U, Kruger U, Middel P, Schinner S, Fuzesi L, Neumann C and Reich K . (2002). J. Invest. Dermatol., 119, 576–582.
Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S and Spiegelman BM . (1998). Mol. Cell, 1, 465–470.
Osawa E, Nakajima A, Wada K, Ishimine S, Fujisawa N, Kawamori T, Matsuhashi N, Kadowaki T, Ochiai M, Sekihara H and Nakagama H . (2003). Gastroenterology, 124, 361–367.
Otto C, Lehrke M and Goke B . (2002). Pharmacogenomics, 3, 99–116.
Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM and Halperin JA . (2001). Cancer Res., 61, 6213–6218.
Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch RJ and Davis RJ . (1995). J. Biol. Chem., 270, 7420–7426.
Rishi AK, Sun RJ, Gao Y, Hsu CK, Gerald TM, Saeed Sheikh M, Dawson MI, Reichert U, Shroot B, Fornace Jr. AJ, Brewer G and Fontana JA . (1999). Nucleic Acids Res., 27, 3111–3119.
Rouse J, Cohen P, Trigon S, Morange M, Alonso-Llamazares A, Zamanillo D, Hunt T and Nebreda AR . (1994). Cell, 78, 1027–1037.
Rumi MA, Sato H, Ishihara S, Kawashima K, Hamamoto S, Kazumori H, Okuyama T, Fukuda R, Nagasue N and Kinoshita Y . (2001). Br. J. Cancer, 84, 1640–1647.
Sakaue M, Adachi H and Jetten AM . (1999). Mol. Pharmacol, 55, 668–676.
Sarkar D, Su ZZ, Lebedeva IV, Sauane M, Gopalkrishnan RV, Valerie K, Dent P and Fisher PB . (2002). Proc. Natl. Acad. Sci. USA, 99, 10054–10059.
Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C and Spiegelman BM . (1998). Nat. Med., 4, 1046–1052.
Smith ML, Chen IT, Zhan Q, Bae I, Chen CY, Gilmer TM, Kastan MB, O'Connor PM and Fornace Jr. AJ . (1994). Science, 266, 1376–1380.
Spiegelman BM . (1998). Diabetes, 47, 507–514.
Sugimura A, Kiriyama Y, Nochi H, Tsuchiya H, Tamoto K, Sakurada Y, Ui M and Tokumitsu Y . (1999). Biochem. Biophys. Res. Commun., 261, 833–837.
Takahashi S, Saito S, Ohtani N and Sakai T . (2001). Cancer Res., 61, 1187–1195.
Takashima T, Fujiwara Y, Higuchi K, Arakawa T, Yano Y, Hasuma T and Otani S . (2001). Int. J. Oncol., 19, 465–471.
Takekawa M and Saito H . (1998). Cell, 95, 521–530.
Tong T, Fan W, Zhao H, Jin S, Fan F, Blanck P, Alomo I, Rajasekaran B, Liu Y, Holbrook NJ and Zhan Q . (2001). Exp. Cell Res., 269, 64–72.
Wang X, Gorospe M and Holbrook NJ . (1999). J. Biol. Chem., 274, 29599–29602.
Yang WL and Frucht H . (2001). Carcinogenesis, 22, 1379–1383.
Yin F, Wakino S, Liu Z, Kim S, Hsueh WA, Collins AR, Van Herle AJ and Law RE . (2001). Biochem. Biophys. Res. Commun., 286, 916–922.
Yoshizawa K, Cioca DP, Kawa S, Tanaka E and Kiyosawa K . (2002). Cancer, 95, 2243–2251.
Acknowledgements
This work was supported in part by the contributions of CALVIN DAKS DDS and Emily Chang. Florian Blaschke was supported by a research fellowship from Philipp Morris Incorporated.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yin, F., Bruemmer, D., Blaschke, F. et al. Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells. Oncogene 23, 4614–4623 (2004). https://doi.org/10.1038/sj.onc.1207598
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207598
- Springer Nature Limited
Keywords
This article is cited by
-
Boron Derivatives Inhibit the Proliferation of Breast Cancer Cells and Affect Tumor-Specific T Cell Activity In Vitro by Distinct Mechanisms
Biological Trace Element Research (2023)
-
MAPK signaling pathway-targeted marine compounds in cancer therapy
Journal of Cancer Research and Clinical Oncology (2021)
-
CB13, a novel PPARγ ligand, overcomes radio-resistance via ROS generation and ER stress in human non-small cell lung cancer
Cell Death & Disease (2020)
-
In vitro and in vivo cytotoxicity of troglitazone in pancreatic cancer
Journal of Experimental & Clinical Cancer Research (2017)
-
Rosiglitazone Suppresses Glioma Cell Growth and Cell Cycle by Blocking the Transforming Growth Factor-Beta Mediated Pathway
Neurochemical Research (2012)